**Regularly Scheduled Series**

**You are invited to the OUHSC Department of Pediatrics Grand Rounds**

**Course No. 25D06**

**Wednesday, February 19, 2025**

**12:15 – 1:15pm**

**To Record Your Attendance:  Text XXXXX to 405-562-5828 during Grand Rounds**

***You will still need to text in your attendance to receive CME and access the survey.***

Participants can text in 15 minutes before the scheduled start, all during, and two hours after the scheduled end (12:00 – 3:15 p.m.).

**\* \* \*SAMIS EDUCATION CENTER\* \* \***

and/or

Join Zoom Meeting

<https://oklahoma.zoom.us/j/93137802976?pwd=WKaF76RQerrmY7fKZIVLbbQgLgpveK.1>

Meeting ID: **931 3780 2976**

Password: **00001111**

One tap mobile

US: [+12133388477,,93137802976#,,,,\*00001111#](tel:+12133388477,,93137802976#,,,,*00001111#) or [+12532158782,,93137802976#,,,,\*00001111#](tel:+12532158782,,93137802976#,,,,*00001111#)

**NOTE**: : The meeting host will admit you to the meeting a few minutes before 12:15.

If you login early, please wait to be admitted.

**Title:**

**“*PDA Stenting: Open Pathways to Improve Care in Cyanotic Heart Disease”***

- - - - - - - - - - - - - - - - - - - -

Presented by:

**Howaida G. El-Said, MD, PhD**

Professor of Pediatric Cardiology

University of California San Diego

Director of Cardiac Cath Lab

Rady Children’s Hospital

Adult Congenital Heart Disease Certified

Invited by: Pediatric Cardiology

***CHF Aliya Hefner Lecture***

OUHSC Department of Pediatrics

**If you wish to view video tapes of past GR, go to** <https://mediasite.ouhsc.edu/Mediasite/Channel/ch-pedsgr>

Note: We do not have permission from all presenters to videotape their presentations.

**A list of upcoming Pediatric GR topics can be found at:** <https://medicine.ouhsc.edu/Academic-Departments/Pediatrics/Research-Education/Grand-Rounds>

**Accreditation Statement:** The University of Oklahoma College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Oklahoma College of Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit™.*  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**ANCC Accreditation Statement:** OU Medicine, Inc. is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

1.00 CNE contact hours will be awarded for meeting the following criteria: 90% attendance of conference, completion and submission of evaluation form.

This educational activity does not include any content that relates to the products and/or services of a commercial interest that would create a conflict of interest.

**ABP MOC Recognition Statement**

**ABP MOC ID# 202329819**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1.00 MOC point(s) in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.

All ABP MOC credits will be reported by December 1 of the current calendar year on your behalf.

For information about ACCME accreditation and ABP MOC for this activity, please email [**Susie-Dealy@ouhsc.edu**](mailto:Susie-Dealy@ouhsc.edu).

By providing your ABP number, you consent to have the OUHSC CPD Office submit your participation in this activity to the ABP through the ACCME PARS system.

**Mitigation Statement:** The University of Oklahoma College of Medicine, Office of Continuing Professional Development has reviewed this activity’s speaker and planner disclosures and has mitigated all relevant financial relationships with ineligible companies, if applicable.

The University of Oklahoma is an equal opportunity institution. [www.ou.edu/eoo](http://www.ou.edu/eoo)

**Accommodation Statement:** For accommodations, please contact Cindy Dibler, 405-271-4401 [cindy-dibler@ouhsc.edu](mailto:cindy-dibler@ouhsc.edu) .

**Disclaimer Statement:** Statements, opinions and results of studies contained in the program are those of the presenters and authors and do not reflect the policy or position of the Board of Regents of the University of Oklahoma (“OU”) nor does OU provide any warranty as to their accuracy or reliability.

**Disclosure & Mitigation Report**

| **Role** | | **First Name** | **Last Name** | **Ineligible Company** | **Nature of Relevant Financial Relationship** | |
| --- | --- | --- | --- | --- | --- | --- |
|  | Planning Member/ Moderator | H. Christine | Allen, MD | I have no financial relationships or affiliations with ineligible companies to disclose. | | |
|  | Planning Member/ Moderator | Muhammad A. | Altaf, MD | I have no financial relationships or affiliations with ineligible companies to disclose. | | |
|  | Planning Member/ Moderator/Presenter | Ami B. | Bax, MD | I have no financial relationships or affiliations with ineligible companies to disclose. | | |
|  | Planning Member/ Moderator | Amanda L. | Bogie, MD | I have no financial relationships or affiliations with ineligible companies to disclose. | | |
|  | Planning Member | Carol L. | Davenport, MSN, NPD-BC | I have no financial relationships or affiliations with ineligible companies to disclose. | | |
|  | Planning Member/ Moderator | Stephanie D. | DeLeon, MD | I have no financial relationships or affiliations with ineligible companies to disclose. | | |
|  | Course Contact | Cindy G. | Dibler | I have no financial relationships or affiliations with ineligible companies to disclose. | | |
|  | Planning Member | Jennifer | Dimmer, APRN | I have no financial relationships or affiliations with ineligible companies to disclose. | | |
|  | Planning Member/Moderator | Marny | Dunlap, MD | I have no financial relationships or affiliations with ineligible companies to disclose. | | |
|  | Planning Member/Moderator | S. Nikki | Ferrin, MD | I have no financial relationships or affiliations with ineligible companies to disclose. | | |
|  | Planning Member/Moderator | Elizabeth | Kutteh, MD | I have no financial relationships or affiliations with ineligible companies to disclose. | | |
|  | Planning Member/ Moderator | Robert W. | Katz, MD | I have no financial relationships or affiliations with ineligible companies to disclose. | | |
|  | Planning Member/ Moderator | Osman | Khan, MD | I have no financial relationships or affiliations with ineligible companies to disclose. | | |
|  | Planning Member/Moderator | Rachna | May, MD | I have no financial relationships or affiliations with ineligible companies to disclose. | | |
|  | Planning Member/Moderator | Nighat | Mehdi, MD | Vertex; Mylan; Aridis; Promise; TDN; Cystic Fibrosis Foundation | Grant/Research Support | |
|  | Planning Member/ Moderator | Arshid | Mir, MD | I have no financial relationships or affiliations with ineligible companies to disclose. | | |
|  | Planning Committee / Moderator/Course Director | Monique | Naifeh, MD, MPH | I have no financial relationships or affiliations with ineligible companies to disclose. | | |
|  | Planning Member/ Moderator | Jane F. | Silovsky, PhD | I have no financial relationships or affiliations with ineligible companies to disclose. | | |
|  | Planning Member/ Moderator | David P. | Sparling, PhD | I have no financial relationships or affiliations with ineligible companies to disclose. | | |
|  | Planning Member/ Moderator | Trent E. | Tipple, MD | I have no financial relationships or affiliations with ineligible companies to disclose. | | |
|  | Planning Member/ Moderator | Donna L. | Tyungu, MD | I have no financial relationships or affiliations with ineligible companies to disclose. | | |
|  | Planning Member/ Moderator | Ikuyo | Yamaguchi, MD, PhD | I have no financial relationships or affiliations with ineligible companies to disclose. | | |
|  | Presenter | Howaida G. | El Said, MD, PhD | Merit Medical | | Consulting Fee |
|  | Dr. El-Said will be discussing experimental or off-label drugs, devices and/or therapies that have not been approved by the FDA. | | | | | |